Integra LifeSciences Announces Launch of New Jarit(R) Take-Apart Laparoscopic Instruments
PLAINSBORO, N.J., March 26, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its new line of Jarit® Take-Apart Laparoscopic instruments. The new instruments allow the components to be fully disassembled, making cleaning and visual inspection easier. Integra will feature the Jarit® Take-Apart Laparoscopic instruments at the 59th Congress of the Association of periOperative Registered Nurses (AORN), March 24-29, 2012, in New Orleans, Louisiana.
This product line addresses the growing concerns of both hospitals and regulatory bodies about the need for instruments that can be more easily cleaned and sterilized. Integra has recently introduced numerous products to enable hospitals to increase the certainty of using clean instruments on every patient. Adding features that increase the ease and visual verification of cleaning are expected to further limit uncertainty for OR personnel.
"These new laparoscopic patterns are an important addition to our instrument portfolio. Long, narrow cannulas and intricately fitting components are a challenge to clean, yet are necessary for minimally invasive surgery. Our new take-apart design balances ease of cleaning with surgeon preference, both of which are important goals in achieving optimal patient care," said Dan Reuvers, President, Integra Surgical.
Integra is a leading provider of surgical instruments used in general surgery, neurosurgery, cardiac surgery and most other surgical modalities, as well as surgical retractor systems and illumination products. Integra's brands include recognized names like Luxtec®, Jarit®, Miltex®, Ruggles®, and Omni-Tract®.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use the products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Gianna Sabella
Director of Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com